MATR3 F115C

MATR3 (Matrin-3) is an RNA-binding protein located in the cell nucleus that plays critical roles in processing genetic information, including splicing (cutting and joining) RNA molecules and transporting messenger RNA [3]. Mutations in MATR3 cause autosomal dominant forms of both ALS and distal myopathy (muscle weakness affecting hands and feet), with the S85C mutation being the most commonly reported disease variant [2]. The F115C mutation analyzed here represents a different pathogenic variant in the same protein that leads to ALS through mechanisms that remain incompletely understood. The AlphaFold2 structure prediction for MATR3 F115C yielded an average confidence score (pLDDT) of 54.7%, which falls well below the 70% threshold typically considered reliable for structural interpretation. This low confidence strongly suggests that the region containing and surrounding the F115C mutation does not adopt a stable, well-defined three-dimensional structure under normal conditions. Instead, this region is likely intrinsically disordered, meaning it remains flexible and lacks a fixed shape. Many RNA-binding proteins contain such disordered regions that become structured only when binding to RNA or protein partners, and these flexible regions are often critical for regulating protein function. Recent research has shown that different MATR3 mutations impair protein function through distinct mechanisms. The well-studied S85C mutation reduces MATR3 solubility (its ability to remain dissolved in the cell) but does not impair its ability to bind RNA, whereas other mutations may affect different functional properties [3]. MATR3 normally prevents aberrant splicing events by blocking the inclusion of "cryptic exons" (incorrect segments) into messenger RNAs, and loss of this function leads to production of defective proteins [3]. Given the low structural confidence for the F115C variant, it is not possible to predict from the AlphaFold model whether this mutation directly disrupts RNA binding surfaces or affects other aspects of MATR3 function. The mutation occurs in a region that may be important for protein-protein interactions or post-translational modifications rather than forming a stable structural core. MATR3 dysfunction appears to contribute to ALS through multiple pathways. The protein regulates expression of genes in the immune system's MHC class II antigen presentation pathway, and MATR3 depletion reduces levels of immune proteins in both general cells and specialized brain immune cells called microglia [4]. Additionally, neuronal activity regulates MATR3 levels through calcium-dependent processes, and the protein can be cleaved by enzymes activated during excessive neuronal excitation, a feature observed in ALS patients [5]. MATR3 also works together with other ALS-associated RNA-binding proteins like TDP-43 and FUS to regulate important neuronal genes such as UNC13A [1]. These findings suggest that F115C and other MATR3 mutations may cause disease by disrupting any or all of these regulatory functions rather than by destabilizing a folded protein structure. The low confidence of the F115C structural prediction limits the ability to make specific mechanistic predictions but provides an important insight: disease-causing effects likely arise from altered protein interactions or modifications in disordered regions rather than from misfolding of a stable structure. Future experimental studies measuring F115C effects on RNA binding, protein solubility, interaction with other RNA-processing factors, and susceptibility to calcium-dependent cleavage will be essential to understand how this variant causes neurodegeneration. Patients with MATR3 mutations typically develop symptoms in adulthood, and the autosomal dominant inheritance pattern means that a single mutated copy of the gene is sufficient to cause disease, suggesting that the mutations may create toxic protein function rather than simply reducing normal MATR3 activity.